As of May 26
| -0.05 / -2.50%|
The 2 analysts offering 12-month price forecasts for InVivo Therapeutics Holdings Corp have a median target of 14.63, with a high estimate of 23.25 and a low estimate of 6.00. The median estimate represents a +650.00% increase from the last price of 1.95.
The current consensus among 2 polled investment analysts is to Buy stock in InVivo Therapeutics Holdings Corp. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.